Keith Loria

Corticosteroids are a mainstay but the introduction of biologics has transformed the management of this severe form of asthma.

The FDA approved proton beam radiation in 1988. But whether it is an improvement over conventional photon radiation as a treatment for many cancers remains an open question.

Devices take some of the pressure off a healthcare system coping with COVID-19.

Healthcare has successfully pivoted and collaborated. But COVID-19 also has spotlighted flaws in how hospitals are financed and the weakness of the public health infrastructure.

Eric Whitaker, M.D., credits influences in high school and medical school with his success. Now he wants to turn his new Medicare Advantage plan, Zing Health, into a training ground for Black and Latino health insurance executives — and has his sights set on unicorn status.

Last year a lull in provider mergers and acquisitions was followed by an uptick. Experts say the disruptive effect of COVID-19 may mean plenty of deals this year.

Bolstering the ACA and addressing healthcare inequities perhaps through Medicaid waivers may top the agenda. Experts see a continuation of support of ACOs and growth in enrollment in Medicare Advantage plans.

Prostate cancer is often “indolent,” so it can be monitored and not treated right away.

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.

The second of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

The first of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

McKesson VP says implementing patient-centeredness involves 13 different types of professionals.

The work of moving away from fee for service is in progress. The results so far? Mixed.

Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.

COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.

A look at how technology is making a difference in the delivery of care during the pandemic.

SGLT2 inhibitors, GLP-1 receptor agonists also tackle cardiovascular disease, renal failure.

Biosimilars to Avastin and Herceptin are catching on.

Potential agents to battle inflammation and other processes move through development pipeline.

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

The veteran healthcare executive says this may be a Netflix vs. Blockbuster moment for hospitals. And health plans may be under pressure to meet the statutory levels for medical spending and recontract with their networks to offer enhanced payments in return for clinical improvement activities.

An off-the-shelf version of CAR-T therapy that uses the immune system’s natural killer cells is a possibility. But the high price of CAR-T shows some doubts about how widely it can be used.

Some hospitals were overwhelmed. But for many providers, COVID-19 has meant the absence of patients - and major drops in revenue. And now there is a possible economic downturn. COVID-19 has hit American healthcare and hit it hard.   

Proving therapeutic equivalence is a major hurdle.

Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.

He was reluctant to take the CEO job, but VanTrieste has the unique nonprofit drug manufacturer surpassing its goals and possibly branching out into the retail market.

The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.

Just as we’ve seen the entire healthcare landscape change in 2020 because of  COVID-19, the world of biosimilars is ever-changing.